Company: GANX
Filing Date: 2025-07-17
Form Type: 8-K
Source: 0001104659-25-068530
Chunk: 3

Company: Gain Therapeutics, Inc.
Filing Date: 2025-07-17
Form: 8-K
Item: Item 3.02
Chunk 3
---
Item 3.02 Unregistered Sales of Equity Securities.

The information contained above in Item 1.01 related to the Underwriter’s
Warrants is hereby incorporated by reference into this Item 3.02. The offer and sale of the Underwriter’s Warrants have not been
registered under the Securities Act and are instead being offered pursuant to the exemption provided in Section 4(a)(2) under
the Securities Act and/or Rule 506(b) promulgated thereunder.

Item 7.01. Regulation FD Disclosure.

On July 15, 2025, the Company issued a press release regarding the
launch of the Offering (the “ Launch Press Release”). On July 16, 2025, the Company issued a press release announcing
that it had priced the Offering (the “Pricing Press Release”). Copies of the Launch Press Release and the Pricing Press
Release are furnished hereto as Exhibit 99.1 and Exhibit 99.2, respectively.

The information in this Current Report on Form 8-K under Item 7.01,
including the information contained in Exhibits 99.1 and 99.2, is being furnished to the SEC and shall not be deemed to be “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities
Act or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

Cautionary Statement Regarding Forward-Looking Statements

Statements contained in this Current Report on Form 8-K regarding matters
that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform
Act of 1995. Such statements may involve risks and uncertainties, such as statements related to the anticipated closing of the Offering
and the amount of proceeds expected from the Offering. The risks and uncertainties involved include the Company’s ability to satisfy
certain conditions to closing on a timely basis or at all, as well as other risks detailed from time to time in the Company’s SEC
filings, including in its annual report on Form 10-K filed with the SEC on March 27, 2025, the preliminary prospectus supplement filed
with the SEC on July 15, 2025, and the final prospectus supplement to be filed with the SEC.

Item